201 related articles for article (PubMed ID: 11802939)
1. [The immunotherapeutic effect of Mycobacterium vaccae vaccine on initially treated pulmonary tuberculosis].
Luo Y;
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Jan; 24(1):43-7. PubMed ID: 11802939
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapeutic effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis].
Luo Y; Lu S; Guo S
Zhonghua Jie He He Hu Xi Za Zhi; 2000 Feb; 23(2):85-8. PubMed ID: 11778496
[TBL] [Abstract][Full Text] [Related]
3. [A clinical study on vaccine of Mycobacterium vaccae in treating pulmonary tuberculosis].
Wang W; Jin G; Ye Y; Xia X; Wang A; Zhuang Y; Li G; Sun H; Wang Z; Lin M; Chen H; Li J; Dan Z; Zhang X
Zhonghua Jie He He Hu Xi Za Zhi; 1999 Feb; 22(2):108-10. PubMed ID: 11820954
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapeutic efficacy of BCG vaccine in pulmonary tuberculosis and its preventive effect on multidrug-resistant tuberculosis].
Lei JP; Xiong GL; Hu QF; Li Y; Zong PL; Tu SH; Tu RY
Zhonghua Yu Fang Yi Xue Za Zhi; 2008 Feb; 42(2):86-9. PubMed ID: 18642658
[TBL] [Abstract][Full Text] [Related]
5. Does immunotherapy with heat-killed Mycobacterium vaccae offer hope for the treatment of multi-drug-resistant pulmonary tuberculosis?
Stanford JL; Stanford CA; Grange JM; Lan NN; Etemadi A
Respir Med; 2001 Jun; 95(6):444-7. PubMed ID: 11421500
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration.
Johnson JL; Kamya RM; Okwera A; Loughlin AM; Nyole S; Hom DL; Wallis RS; Hirsch CS; Wolski K; Foulds J; Mugerwa RD; Ellner JJ
J Infect Dis; 2000 Apr; 181(4):1304-12. PubMed ID: 10753731
[TBL] [Abstract][Full Text] [Related]
7. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy.
Jenkins PA; Campbell IA; Banks J; Gelder CM; Prescott RJ; Smith AP
Thorax; 2008 Jul; 63(7):627-34. PubMed ID: 18250184
[TBL] [Abstract][Full Text] [Related]
8. An open study to assess the efficacy clinically and immunologically of M. vaccae vaccine in patients with atopic dermatitis.
Davies MG; Symons C; Shaw S; Kaminski ER
J Dermatolog Treat; 2006; 17(2):74-7. PubMed ID: 16766329
[TBL] [Abstract][Full Text] [Related]
9. [A controlled clinical study on the efficacy of recombinant human interleukin-2 in the treatment of pulmonary tuberculosis].
Chu NH; Zhu LZ; Yie ZZ; Yuan SL; Wang JY; Xu JL; Ma LP
Zhonghua Jie He He Hu Xi Za Zhi; 2003 Sep; 26(9):548-51. PubMed ID: 14521759
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Durban Immunotherapy Trial Group.
Lancet; 1999 Jul; 354(9173):116-9. PubMed ID: 10408487
[TBL] [Abstract][Full Text] [Related]
11. [Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis].
Zheng XM; Li SM; Xing BC
Di Yi Jun Yi Da Xue Xue Bao; 2004 May; 24(5):574-5, 578. PubMed ID: 15151838
[TBL] [Abstract][Full Text] [Related]
12. [Bacteriological examination on needle biopsy specimens of cavity and tuberculoma after a short course chemotherapy in initially sputum positive pulmonary tuberculosis patients].
Lu SH; Wang TP; Lü W; Du RH; Wang HX; Wang ZR
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Dec; 29(12):832-4. PubMed ID: 17327088
[TBL] [Abstract][Full Text] [Related]
13. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis.
Waddell RD; Chintu C; Lein AD; Zumla A; Karagas MR; Baboo KS; Habbema JD; Tosteson AN; Morin P; Tvaroha S; Arbeit RD; Mwinga A; von Reyn CF
Clin Infect Dis; 2000 Jun; 30 Suppl 3():S309-15. PubMed ID: 10875806
[TBL] [Abstract][Full Text] [Related]
15. [Effects of vaccae on airway inflammation and Th1/Th2 cytokines in sensitized mice].
Xie Q; Bian R; Wu K; Zheng X
Zhonghua Jie He He Hu Xi Za Zhi; 2002 Aug; 25(8):488-92. PubMed ID: 12425837
[TBL] [Abstract][Full Text] [Related]
16. Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis.
Katoch K; Singh P; Adhikari T; Benara SK; Singh HB; Chauhan DS; Sharma VD; Lavania M; Sachan AS; Katoch VM
Vaccine; 2008 Feb; 26(9):1228-34. PubMed ID: 18243430
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Mycobacterium vaccae immunotherapy for patients with tuberculosis: A systematic review and meta-analysis.
Huang CY; Hsieh WY
Hum Vaccin Immunother; 2017 Sep; 13(9):1960-1971. PubMed ID: 28604170
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy.
Narang T; Kaur I; Kumar B; Radotra BD; Dogra S
Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):105-14. PubMed ID: 16830653
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy with oral, heat-killed, Mycobacterium vaccae in patients with moderate to advanced pulmonary tuberculosis.
Dlugovitzky D; Notario R; Martinel-Lamas D; Fiorenza G; Farroni M; Bogue C; Stanford C; Stanford J
Immunotherapy; 2010 Mar; 2(2):159-69. PubMed ID: 20635925
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa.
Onyebujoh PC; Abdulmumini T; Robinson S; Rook GA; Stanford JL
Respir Med; 1995 Mar; 89(3):199-207. PubMed ID: 7746913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
